Should I buy or sell Sera Prognostics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SERA shares. View SERA analyst ratings or view top-rated stocks .

What is Sera Prognostics' stock price target for 2024?

2 analysts have issued twelve-month price objectives for Sera Prognostics' shares. Their SERA share price targets range from $2.75 to $2.75. On average, they predict the company's share price to reach $2.75 in the next year. This suggests that the stock has a possible downside of 66.7%. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts .

How have SERA shares performed in 2024?

Sera Prognostics' stock was trading at $5.98 at the beginning of the year. Since then, SERA stock has increased by 38.1% and is now trading at $8.26. View the best growth stocks for 2024 here .

When is Sera Prognostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our SERA earnings forecast .

How were Sera Prognostics' earnings last quarter?

Sera Prognostics, Inc. (NASDAQ:SERA) released its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25). The business had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.10 million. Sera Prognostics had a negative trailing twelve-month return on equity of 46.35% and a negative net margin of 11,843.79%.

What ETF holds Sera Prognostics' stock?

Invesco DWA SmallCap Momentum ETF holds 640,635 shares of SERA stock, representing 0.76% of its portfolio.

When did Sera Prognostics IPO?

Sera Prognostics (SERA) raised $75 million in an IPO on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share.

Who are Sera Prognostics' major shareholders?

Sera Prognostics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (6.24%), Vanguard Group Inc. (2.76%), AWM Investment Company Inc. (1.80%), Commonwealth Equity Services LLC (0.18%), Sanders Morris Harris LLC (0.06%) and Marquette Asset Management LLC (0.04%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt. View institutional ownership trends .

How do I buy shares of Sera Prognostics?

Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SERA

Sera Prognostics (SERA) Stock Price, News & Analysis

→ CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad)

Free SERA Stock Alerts

$8.26

-0.12 (-1.43%)

(As of 05/17/2024 ET)

Compare

Today's Range: $8.13
▼
$8.45
50-Day Range: $8.26
▼
$11.69
52-Week Range: $1.52
▼
$12.35

Volume: 141,804 shs
Average Volume: 124,117 shs
Market Capitalization: $269.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.75

Get Sera Prognostics alerts:

Sera Prognostics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 66.7% Downside
$2.75 Price Target
Short Interest: Healthy
1.11% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.31
Based on 11 Articles This Week
Insider Trading: Selling Shares
$1.18 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.94) to ($0.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

794th out of 921 stocks

Medical Laboratories Industry

18th out of 19 stocks

1.3

Analyst's Opinion

Consensus Rating
Sera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Sera Prognostics has only been the subject of 1 research reports in the past 90 days.
Read more about Sera Prognostics' stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
1.11% of the float of Sera Prognostics has been sold short.
Short Interest Ratio / Days to Cover
Sera Prognostics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sera Prognostics has recently decreased by 15.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sera Prognostics does not currently pay a dividend.
Dividend Growth
Sera Prognostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SERA.

2.4

News and Social Media Coverage

News Sentiment
Sera Prognostics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Sera Prognostics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for SERA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
MarketBeat Follows
2 people have added Sera Prognostics to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,177,103.00 in company stock.
Percentage Held by Insiders
15.80% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Sera Prognostics' insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sera Prognostics are expected to grow in the coming year, from ($0.94) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sera Prognostics is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sera Prognostics is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sera Prognostics has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Sera Prognostics' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Banyan Hill Publishing

CEO of Biggest AI Chipmaker Just Dropped a Bombshell…

Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.

Click on Adam's shiny forehead for more details.

About Sera Prognostics Stock (NASDAQ:SERA)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

SERA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SERA Stock News Headlines

May 16 at 1:39 PM | insidertrades.com

Sera Prognostics, Inc. (NASDAQ:SERA) Insider Paul Kearney Sells 10,387 Shares

May 11, 2024 | insidertrades.com

Sera Prognostics, Inc. (NASDAQ:SERA) Insider John J. Boniface Sells 4,902 Shares